Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients

Not Applicable

Completed

Conditions: Immunosuppression

Interventions: Drug: Tacrolimus
Drug: Prednisone
Drug: Everolimus
Drug: Mycophenolate mofetil

First Posted Date: 2016-11-03

Last Posted Date: 2019-12-24

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 40

Registration Number: NCT02954198

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

Phase 1

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Decitabine

First Posted Date: 2016-11-01

Last Posted Date: 2020-03-11

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 58

Registration Number: NCT02951728

Locations: 🇨🇳
Shanghai Ruijin Hospital, Shanghai, China

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Phase 2

Recruiting

Conditions: Stage II Prostate Adenocarcinoma
Stage III Prostate Adenocarcinoma

Interventions: Drug: Abiraterone Acetate
Drug: Androgen Receptor Antagonist ARN-509
Other: Quality-of-Life Assessment
Biological: Gonadotropin-releasing Hormone Analog
Drug: Prednisone
Other: Questionnaire Administration
Procedure: Radical Prostatectomy

First Posted Date: 2016-10-31

Last Posted Date: 2023-09-26

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 90

Registration Number: NCT02949284

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

Phase 1

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Niraparib
Drug: Apalutamide
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2016-10-05

Last Posted Date: 2020-07-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 34

Registration Number: NCT02924766

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Phase 2

Completed

Conditions: Kidney Transplantation
Primary Focal Segmental Glomerulosclerosis (FSGS)

Interventions: Drug: Bleselumab
Drug: Basiliximab
Drug: Mycophenolate Mofetil (MMF)
Drug: Tacrolimus Capsules
Drug: Methylprednisone
Drug: Prednisone

First Posted Date: 2016-10-03

Last Posted Date: 2024-12-04

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 67

Registration Number: NCT02921789

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

and more 20 locations

Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis

Phase 4

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Prednisone
Drug: Methylprednisolone

First Posted Date: 2016-10-03

Last Posted Date: 2023-02-23

Lead Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Target Recruit Count: 75

Registration Number: NCT02921555

Locations: 🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Astúrias, Spain
🇪🇸
Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
🇪🇸
Hospital de Galdakao, Galdakao, Bilbao, Spain

and more 26 locations

PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage

Phase 2

Conditions: Lymphoma

Interventions: Drug: pegaspargase
Drug: Gemcitabine
Drug: Cyclophosphamide
Drug: Oxaliplatin
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Vincristine
Radiation: IMRT
Drug: Prednisone

First Posted Date: 2016-09-29

Last Posted Date: 2020-01-28

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT02918747

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone

Phase 2

Completed

Conditions: Croticosteroid Therapy
ITP

Interventions: Drug: High dose Dexamethasone pulses
Drug: Prednisone

First Posted Date: 2016-09-26

Last Posted Date: 2017-09-18

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 36

Registration Number: NCT02914054

Locations: 🇮🇷
IUMS, Isfahan, Iran, Islamic Republic of

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

Phase 1

Active, not recruiting

Conditions: Prostate Cancer Metastatic

Interventions: Drug: Apalutamide
Drug: Abiraterone acetate
Drug: Docetaxel
Drug: Prednisone

First Posted Date: 2016-09-23

Last Posted Date: 2024-06-27

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 16

Registration Number: NCT02913196

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
GU Research Network/Urology Cancer Center, Omaha, Nebraska, United States

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Primary Effusion Lymphoma
B-Cell Neoplasm

Interventions: Drug: Lenalidomide
Drug: Rituximab
Drug: Prednisone
Drug: Etopside
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide

First Posted Date: 2016-09-22

Last Posted Date: 2024-10-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT02911142

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy